These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32770252)

  • 1. Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction.
    Wang IK; Yen TH; Chen CH; Hsu SP; Sun Y; Lien LM; Chang WL; Lai TC; Chen PL; Chen CC; Huang PH; Lin CH; Su YC; Lin MC; Li CY; Sung FC; Hsu CY;
    QJM; 2022 Jan; 114(12):848-856. PubMed ID: 32770252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebral hemorrhage after thrombolytic therapy in acute ischemic stroke patients with renal dysfunction.
    Chao TH; Lin TC; Shieh Y; Chang TY; Hung KL; Liu CH; Lee TH; Chang YJ; Lee JD; Chang CH
    Eur Neurol; 2013; 70(5-6):316-21. PubMed ID: 24080988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favourable renal outcomes after intravenous thrombolytic therapy for acute ischemic stroke: Clinical implication of kidney-brain axis.
    Chang TH; Chiu PF; Tsai CC; Chang CH; Wu CL; Kor CT; Li JR; Kuo CL; Huang CS; Chu CC; Lin CM; Chang CC
    Nephrology (Carlton); 2019 Sep; 24(9):896-903. PubMed ID: 30334303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the safety and efficacy of intravenous thrombolysis for acute ischemic stroke patients with a history of intracerebral hemorrhage: a systematic review and meta-analysis.
    Goh S; Tan NHW; Tan CH; Leow AST; Sia CH; Ho AFW; Lim MJR; Yeo LLL; Tan BYQ
    J Thromb Thrombolysis; 2022 Feb; 53(2):485-494. PubMed ID: 34302590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
    Rao ZZ; Gu HQ; Wang XW; Xie XW; Yang X; Wang CJ; Zhao X; Xian Y; Wang YL; Li ZX; Xiao RP; Wang YJ;
    J Am Heart Assoc; 2019 Oct; 8(20):e012052. PubMed ID: 31595836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.
    Tong X; George MG; Yang Q; Gillespie C
    Int J Stroke; 2014 Aug; 9(6):728-34. PubMed ID: 24024962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
    Mehta RH; Cox M; Smith EE; Xian Y; Bhatt DL; Fonarow GC; Peterson ED;
    Stroke; 2014 Aug; 45(8):2263-9. PubMed ID: 25070958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
    Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED
    JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke.
    Zhou XY; Wang SS; Collins ML; Davis SM; Yan B
    J Clin Neurosci; 2010 Aug; 17(8):988-92. PubMed ID: 20510615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.
    Merkler AE; Salehi Omran S; Gialdini G; Lerario MP; Yaghi S; Elkind MSV; Navi BB
    Stroke; 2017 Aug; 48(8):2282-2284. PubMed ID: 28679847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke.
    Martin-Schild S; Hallevi H; Albright KC; Khaja AM; Barreto AD; Gonzales NR; Grotta JC; Savitz SI
    Arch Neurol; 2008 Sep; 65(9):1174-8. PubMed ID: 18779419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.
    Heuschmann PU; Berger K; Misselwitz B; Hermanek P; Leffmann C; Adelmann M; Buecker-Nott HJ; Rother J; Neundoerfer B; Kolominsky-Rabas PL; ;
    Stroke; 2003 May; 34(5):1106-13. PubMed ID: 12663875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.